After winning a preliminary reprieve at the end of 2025, #hospitals that challenged the start of an #HHS pilot scheme to implement a new #rebatemodel for #medicines provided to low-income people in the #US have scored another victory.

People who use drugs like #GLP1 agonists to lose #weightregain it more quickly than those who use a conventional approach of #diet and #exercise, according to a new study.

#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer. pharmaphorum.com/news/hengrui...

#OpenAI has announced #ChatGPTHealth, which promises to bring users' #medicalrecords and #healthandwellnessapps like Apple Fitness and MyFitnessPal into one place, alongside their health-related conversations with the #AI assistant. pharmaphorum.com/news/openai-...

#Hutchmed is preparing to file for approval of a drug for the rare #autoimmune disorder warm antibody autoimmune haemolytic #anaemia (#wAIHA) in #China, after chalking up a win in a pivotal phase 2/3 trial. pharmaphorum.com/news/hutchme...

#EliLilly is reported to be eyeing a $1 billion-plus takeover of #VentyxBiosciences that, if confirmed, suggests 2026 could follow the bumper pharma #M&A trend that started last year.

#Bayer's agrochemicals unit #Monsanto has filed #lawsuits in the US against the manufacturers of #mRNA-based COVID-19 vaccines, claiming that they used its #patent-protected technology in their products. pharmaphorum.com/news/bayers-...

Eight digital health technologies (#DHTs) designed to support people with #asthma can be used by the #NHS in England while additional evidence of their benefits is gathered. pharmaphorum.com/news/nice-en...

#GSK's antisense-based drug for chronic #hepatitisB (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease. pharmaphorum.com/news/gsk-pre...

In what is thought to be the first major pharma #M&A deal of the year, #Amgen has bought Oxford, UK-based #biotech #DarkBlueTherapeutics (DBT), which specialises in #cancer therapies. pharmaphorum.com/news/amgen-i...

For a second time, #EliLilly has turned to Boston biotech #NimbusTherapeutics to add a potential #weightloss therapy to its pipeline. pharmaphorum.com/news/lilly-t...

#Alumis is preparing to file its oral #TYK2inhibitor envudeucitinib as a treatment for #psoriasis later this year, after a pair of positive phase 3 trials.

#NHSEngland has said that the new #onlinehospital, due to launch next year, will focus initially on nine common conditions, including #menopause and #prostate health.

Chinese #RNA-based medicine developer Suzhou #Ribo Life Science has filed a #HongKong #IPO, aiming to raise new funds for its lead RBD4059 drug candidate for #thromboticdiseases.

The #CDC has upended the #childhoodvaccination schedule, cutting the number of recommended #immunisations in a move that the #Trump administration says brings the US into line with the practice in Denmark. pharmaphorum.com/news/cdc-cut...

US biotech #AktisOncology has filed IPO documents with the Securities and Exchange Commission (#SEC), in what could be the first #biotech listing on the #Nasdaq in 2026. pharmaphorum.com/news/aktis-o...

Fresh from its IPO at the end of last year, #InsilicoMedicine has added to its stable of partners after signing a new #alliance with #Servier that could be worth up to $888 million. pharmaphorum.com/news/insilic...

#GSK has claimed an important new approval for #Nucala in chronic obstructive pulmonary disease (#COPD), in #China, which is estimated to account for around a quarter of the #globalpatientpopulation. pharmaphorum.com/news/china-c...

#Sanofi could be months away from wider US approval for #Tzield, its first-in-class drug for delaying the progression of #type1diabetes (T1D), in #children as young as one. pharmaphorum.com/news/sanofi-...

#NovoNordisk has wasted no time in launching its oral version of the weight loss drug #Wegovy in the US after its approval by the FDA, as 2025 drew to a close. pharmaphorum.com/news/novo-no...

#NICE has said #Biogen's Tysabri can now be used by the #NHS in England and Wales to treat highly active relapsing-remitting #multiplesclerosis (MS), along with a lower-cost #biosimilar version of the drug.

#NovoNordisk has been handed a crucial legal win by #China's Supreme Court, which has upheld the company's #patent protection on #GLP1 agonist #semaglutide used for #diabetes and #weightloss. pharmaphorum.com/news/china-d...

As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to #CorceptTherapeutics with a decision not to approve #relacorilant, a drug for a rare #hormonaldisorder that causes #highbloodpressure.

Denmark's #Genmab has decided not to continue the development of a drug for #cancer, acasunlimab, which had reached phase 3 testing, after a #review of its medicines #pipeline. pharmaphorum.com/news/genmab-...

The FDA's usual end-of-year flurry of #regulatoryapprovals is a little lighter than usual, but the agency has delivered some end-of-year cheer to #VandaPharma after giving the go-ahead to its drug for #motionsickness. pharmaphorum.com/news/vanda-e...

One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.

Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.

A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026. pharmaphorum.com/news/no-chri...

More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.

CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.

CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry.

The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.

AstraZeneca will voluntarily take its #anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects. #pharmanews pharmaphorum.com/news/andexxa...

Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere. #pharmadeals #pharmanews pharmaphorum.com/news/ipsen-l...

AstraZeneca has had a setback in its #oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 #lungcancer trial. #pharmanews pharmaphorum.com/news/azs-atr...

Nine more #pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme. pharmaphorum.com/news/nine-mo... #pharmanews #marketaccess #lifesciences

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market. pharmaphorum.com/news/biomari... #BiotechDeals #MergersAndAcquisitions #LifeSciences #PharmaNews #BiotechBusiness

The #BIOSECUREAct, now part of the National Defense Authorization Act (#NDAA), will put in motion #US government-wide restrictions on ‘#biotechnology companies of concern’ and eventually bar agencies from procuring their biotech equipment or services. pharmaphorum.com/news/us-bios...

#Moderna's #mRNA-based #pandemic #fluvaccine – which had federal funding pulled earlier this year amid an increasingly vaccine-sceptic stance by the #Trumpadministration – has been thrown a lifeline by an international consortium.

Our round-up of #financings in the biotech arena this week is led by a $125 million Series A for #AmbrosTherapeutics, a start-up formed to develop a drug for a rare #paindisorder that is already on the market in Italy.

#JohnsonandJohnson has claimed FDA approval for #RybrevantFaspro, a subcutaneous version of its EGFRxMET #bispecificantibody, for all the indications approved for the current, intravenous formulation. #NSCLC pharmaphorum.com/news/jjs-sub...

One criticism of injectable #weightloss drugs is that people tend to put the pounds back on after they stop taking them. Could a new generation of #oraltherapies address that issue? buff.ly/YWzVN7W

#DaiichiSankyo and #AstraZeneca have pressed swiftly to file for approval of their #TROP2-targeting drug Datroway for triple-negative #breastcancer (TNBC) in the #EU, shortly after reporting positive #survivaldata in a pivotal trial.

Armed with positive results in two phase 3 trials, #Takeda intends to file for approval of its oral #psoriasis therapy zasocitinib in the #US and other countries next year, with #BristolMyersSquibb's Sotyktu in its sights. buff.ly/uIoOyTt

The next two discretionary #priorityvouchers to be awarded by the #FDA are reported to be heading for two #MSD candidates with blockbuster potential. pharmaphorum.com/news/msd-cla...

There has been a flurry of new #licensing #deals in the last few days, with #BristolMyersSquibb, #Sanofi, #Pfizer, #Roche, and little #YarrowBioscience all adding to their R&D #pipelines. pharmaphorum.com/news/year-en...

Privately-held drug developer #LIBTherapeutics has claimed #FDA approval for a new once-monthly #PCSK9inhibitor – Lerochol – that can be used to reduce #cholesterol levels. pharmaphorum.com/news/lib-tak...